The most important mode of action is the synthetic lethality of tumor cells in ARID1A mutated cancers with co-occurring mutations of genes pertaining to pathways including the PI3K pathway [55,56,57,58], SRC family kinases [59], DNA-damage repair pathways [60], tumor immune pathway [61], p53 targets/telomerase activation [22,54], Wnt Pathway/PP2A pathway [21,22,62,63], and EZH2 histone methyltransferase as well as BET pathways [48,64,65]. This evidence concerns the gene ARID1A and cancer.